Impacts of Tocolytics on Maternal and Neonatal Glucose Levels in Women With Gestational Diabetes Mellitus.
Humans
Female
Pregnancy
Diabetes, Gestational
/ drug therapy
Tocolytic Agents
/ therapeutic use
Blood Glucose
/ analysis
Retrospective Studies
Adult
Nifedipine
/ therapeutic use
Infant, Newborn
Hypoglycemia
Ritodrine
/ therapeutic use
Vasotocin
/ analogs & derivatives
Logistic Models
Hyperglycemia
/ drug therapy
Odds Ratio
Obstetric Labor, Premature
/ drug therapy
Pregnancy Outcome
Republic of Korea
Atosiban
Gestational Diabetes
Maternal Hyperglycemia
Neonatal Hypoglycemia
Nifedipine
Ritodrine
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
received:
14
04
2024
accepted:
03
07
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
We investigated the impacts of tocolytic agents on maternal and neonatal blood glucose levels in women with gestational diabetes mellitus (GDM) who used tocolytics for preterm labor. This multi-center, retrospective cohort study included women with GDM who were admitted for preterm labor from twelve hospitals in South Korea. We excluded women with multiple pregnancies, anomalies, overt DM diagnosed before pregnancy or 23 weeks of gestation, and women who received multiple tocolytics. The patients were divided according to the types of tocolytics; atosiban, ritodrine, and nifedipine group. We collected baseline maternal characteristics, pregnancy outcomes, maternal glucose levels during hospitalization, and neonatal glucose levels. We compared the frequency of maternal hyperglycemia and neonatal hypoglycemia among three groups. A multivariate logistic regression analysis was performed to evaluate the contributing factors to the occurrence of maternal hyperglycemia and neonatal hypoglycemia. A total of 128 women were included: 44 (34.4%), 51 (39.8%), and 33 (25.8%) women received atosiban, ritodrine, and nifedipine, respectively. Mean fasting blood glucose (FBG) (112.3, 109.6, and 89.5 mg/dL, There is an increased risk of maternal hyperglycemia and neonatal hypoglycemia in women with GDM using atosiban and ritodrine tocolytics for preterm labor compared to those using nifedipine.
Sections du résumé
BACKGROUND
BACKGROUND
We investigated the impacts of tocolytic agents on maternal and neonatal blood glucose levels in women with gestational diabetes mellitus (GDM) who used tocolytics for preterm labor.
METHODS
METHODS
This multi-center, retrospective cohort study included women with GDM who were admitted for preterm labor from twelve hospitals in South Korea. We excluded women with multiple pregnancies, anomalies, overt DM diagnosed before pregnancy or 23 weeks of gestation, and women who received multiple tocolytics. The patients were divided according to the types of tocolytics; atosiban, ritodrine, and nifedipine group. We collected baseline maternal characteristics, pregnancy outcomes, maternal glucose levels during hospitalization, and neonatal glucose levels. We compared the frequency of maternal hyperglycemia and neonatal hypoglycemia among three groups. A multivariate logistic regression analysis was performed to evaluate the contributing factors to the occurrence of maternal hyperglycemia and neonatal hypoglycemia.
RESULTS
RESULTS
A total of 128 women were included: 44 (34.4%), 51 (39.8%), and 33 (25.8%) women received atosiban, ritodrine, and nifedipine, respectively. Mean fasting blood glucose (FBG) (112.3, 109.6, and 89.5 mg/dL,
CONCLUSION
CONCLUSIONS
There is an increased risk of maternal hyperglycemia and neonatal hypoglycemia in women with GDM using atosiban and ritodrine tocolytics for preterm labor compared to those using nifedipine.
Identifiants
pubmed: 39228183
pii: 39.e236
doi: 10.3346/jkms.2024.39.e236
doi:
Substances chimiques
Tocolytic Agents
0
Blood Glucose
0
Nifedipine
I9ZF7L6G2L
Ritodrine
I0Q6O6740J
Vasotocin
W6S6URY8OF
atosiban
081D12SI0Z
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e236Subventions
Organisme : Ministry of Health and Welfare
ID : HC23C0114
Pays : Korea
Organisme : Korean Society of Maternal-Fetal Medicine Outstanding Multicenter Research Project Award
Pays : Korea
Informations de copyright
© 2024 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
Hyun Soo Park and Hyun-Joo Seol participated in the Tractocile (atosiban) Advisory Board and received consulting fees from Ferring Pharmaceuticals Korea on October 24, 2023. Other authors have no potential conflicts of interest.